
|Articles|February 1, 2003
New use permitted: FDA approves latanoprost as first-line IOP reducer
Peapack, NJ-Pharmacia Ophthalmology will begin making its latanoprost ophthalmic solution(Xalatan) available for initial treatment of elevated eye pressure associated with open-angle glaucoma or ocular hypertension.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
2
Study identifies 6 key genes linking air pollution to dry eye disease
3
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
4
Avisi Technologies releases positive 12-month data from VITA Trial
5


















































.png)


